Overcoming BRAF and CDK4/6 inhibitor resistance by inhibiting MAP3K3-dependent protection against YAP lysosomal degradation

참고문헌 (60)

1. Moroishi, T., "The emerging roles of YAP and TAZ in cancer", Nat. Rev. Cancer, 15, pp.73~79 (2015)
2. Pan, D., "The hippo signaling pathway in development and cancer", Dev. Cell, 19, pp.491~505 (2010)
3. Kim, M. H., "Role of YAP", TAZ transcriptional regulators in resistance to anti-cancer therapies, 2017, pp.74, 1457~1474
4. Wang, W., "Tankyrase inhibitors target YAP by stabilizing angiomotin family proteins", Cell Rep, 13, pp.524~532 (2015)
5. Seo, J., "MK5 regulates YAP stability and is a molecular target in YAP-driven cancers", Cancer Res, 79, pp.6139~6152 (2019)
6. Kaneda, A., "The novel potent TEAD inhibitor, K-975, inhibits YAP1", TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma, 2020, pp.10, 4399~4415
7. Soude, A., "Discovery of YAP-TEAD protein-protein interaction(PPI)inhibitors for cancer therapy", Cancer Res, 76, pp.894~894 (2016)
8. Chen, Q., "Homeostatic control of Hippo signaling activity revealed by an endogenous activating mutation in YAP", Genes Dev, 29, pp.1285~1297 (2015)
9. Zhao, B., "Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control", Genes Dev, 21, pp.2747~2761 (2007)
10. Zhao, B., "A coordinated phos phorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP)", Genes Dev, 24, pp.72~85 (2010)
11. Elosegui-Artola, A., "Force triggers YAP nuclear entry by regulating transport across nuclear pores", Cell, 171, pp.1397~1410 (2017)
12. Hong, A. W., "Osmotic stress-induced phosphorylation by NLK at Ser128activates YAP", EMBO Rep, 18, pp.72~86 (2017)
13. Moon, S., "Phosphorylation by NLK inhibits YAP-14-3-3-interactions and induces its nuclear localization", EMBO Rep, 18, pp.61~71 (2017)
14. Wada, K., "Hippo pathway regulation by cell morphology and stress fibers", Development, 138, pp.3907~3914 (2011)
15. Meng, Z., "MAP4K family kinases act in parallel to MST1", 2 to activate LATS1, Nat. Commun, pp.2015, 6[DOI]
16. Zheng, Y., "Identification of Happyhour", MAP4K as alternative Hpo, Dev. Cell, pp.2015, 34[DOI]
17. Li, L., "MEK1 promotes YAP and their interaction is critical for tumorigenesis in liver cancer", FEBS Lett, 587, pp.3921~3927 (2013)
18. Liu, Z., "MAPK-mediated YAP activation controls mechanical-tension-induced pulmonary alveolar regeneration", Cell Rep, 16, pp.1810~1819 (2016)
19. Muranen, T., "ERK and p38 MAPK activities determine sensitivity to PI3K", mTOR inhibition via regulation of MYC and YAP, 2016, pp.76, 7168~7180
20. Uhlik, M. T., "Rac-MEKK3-MKK3 scaffolding for p38 MAPK activation during hyperosmotic shock", Nat. Cell Biol, 5, pp.1104~1110 (2003)
21. Chao, T. H., "MEKK3 directly regulates MEK5 activity as part of the big mitogen-activated protein kinase 1(BMK1)sig naling pathway", J. Biol. Chem, 274, pp.36035~36038 (1999)
22. Samanta, A. K., "Overexpression of MEKK3confers resistance to apoptosis through activation of NFkappaB", J. Biol. Chem, 279, pp.7576~7583 (2004)
23. Hasan, R., "Mitogen activated protein kinase kinase kinase 3(MAP3K3", MEKK3)overexpression is an early event in esophageal tumorigenesis and is a predictor of poor disease prognosis, 2014, pp.14, 2~
24. Jia, W., "MAP3K3 overexpression is associated with poor survival in ovarian carcinoma", Hum. Pathol, 50, pp.162~169 (2016)
25. Cao, X. Q., "MEKK3 and survivin expression in cervical cancer : association with clinicopathological factors and prognosis", Asian Pac. J. Cancer Prev, 15, pp.5271~5276 (2014)
26. Santoro, R., "MEKK3 sustains EMT and stemness in pancreatic cancer by regulating YAP and TAZ transcriptional activity", Anticancer Res, 38, pp.1937~1946 (2018)
27. Kim, Y. J., "Genome-wide RNA interference screening reveals a COPI-MAP2K3pathway required for YAP regulation", Proc. Natl Acad. Sci. USA, 117, pp.19994~20003 (2020)
28. Kim, M. H., "Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP", TAZ activation, 2016, pp.35, 462~478
29. Blonska, M., "Restoration of NF-kappaB activation by tumor necrosis factor alpha receptor complex-targeted MEKK3 in receptor interacting protein-deficient cells", Mol. Cell Biol, 24, pp.10757~10765 (2004)
30. Ma, C. X., "NeoPalAna : neoadjuvant palbociclib, a cyclin-dependent kinase 4", 6inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer, 2017, pp.23, 4055~4065
31. Hanzelmann, S., "GSVA : gene set variation analysis for microarray and RNA-seq data", BMC Bioinform, 14, pp.7~ (2013)
32. Subramanian, A., "Gene set enrichment analysis : a knowledge-based approach for interpreting genome-wide expression profiles", Proc. Natl Acad. Sci. USA, 102, pp.15545~15550 (2005)
33. Finch-Edmondson, M. L., "TAZ protein accumulation is negatively regulated by YAP abundance in mammalian cells", J. Biol. Chem, 290, pp.27928~27938 (2015)
34. Liang, N., "Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex", J. Exp. Med, 211, pp.2249~2263 (2014)
35. Wang, S., "YAP antagonizes innate antiviral immunity and is targeted for lysosomal degradation through IKKvarepsilon-mediated phosphorylation", Nat. Immunol, 18, pp.733~743 (2017)
36. Lee, Y. A., "Autophagy is a gatekeeper of hepatic differentiation and carci nogenesis by controlling the degradation of Yap", Nat. Commun, 9, pp.4962~ (2018)
37. Chen, T. H., "YAP promotes myogenic differentiation via the MEK5-ERK5pathway", FASEB J, 31, pp.2963~2972 (2017)
38. Chen, Y. A., "WW domain-containing proteins YAP and TAZ in the hippo pathway as key regulators in stemness maintenance, tissue homeostasis, and tumorigenesis", Front Oncol, 9, pp.60~ (2019)
39. Choi, J. P., "Ponatinib (AP24534) inhibits MEKK3-KLF signaling and prevents formation and progression of cerebral cavernous malformations", Sci. Adv, 4, pp.eaau0731~ (2018)
40. Tu, K., "Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma", Mol. Cancer, 13, pp.110~ (2014)
41. Lin, X., "Interaction domains of p62 : a bridge between p62 and selective autophagy", DNA Cell Biol, 32, pp.220~227 (2013)
42. Li, Z., "Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4", 6Inhibitors via the Hippo Pathway, 2018, pp.34, 893~905
43. Turner, N. C., "Palbociclib in hormone-receptor-positive advanced breast cancer", N. Engl. J. Med, 373, pp.209~219 (2015)
44. Finn, R. S., "Palbociclib and letrozole in advanced breast cancer", N. Engl. J. Med, 375, pp.1925~1936 (2016)
45. Guo, P., "High expression of TAZ", YAP promotes the progression of malignant melanoma and affects the postoperative survival of patients, 2018, pp.73, 662~665
46. Nallet-Staub, F., "Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in cutaneous melanoma", J. Invest. Dermatol, 134, pp.123~132 (2014)
47. Boyle, E. I., "GO : : TermFinder–open source software for accessing Gene Ontology information and finding significantly enriched Gene Ontology terms associated with a list of genes", Bioinformatics, 20, pp.3710~3715 (2004)
48. Yu, F. X., "Hippo pathway in organ size control, tissue homeostasis, and cancer", Cell, 163, pp.811~828 (2015)
49. Wang, "Comprehensive molecular characterization of the hippo signaling pathway in cancer", Cell Rep, 25, pp.1304~1317 (2018)
50. Totaro, A., "YAP", TAZ upstream signals and downstream responses, 2018, pp.20, 888~899
51. Fritz, A., "Phosphorylation of serine 526 is required for MEKK3 activity, and association with 14-3-3blocks dephosphorylation", J. Biol. Chem, 281, pp.6236~6245 (2006)
52. Linares, J. F., "Amino acid activation of mTORC1 by a PB1-domain-driven kinase complex cascade", Cell Rep, 12, pp.1339~1352 (2015)
53. Yao, J., "Interleukin-1(IL-1)-induced TAK1-dependent Versus MEKK3dependent NFkappaB activation pathways bifurcate at IL-1 receptor-associated kinase modification", J. Biol. Chem, 282, pp.6075~6089 (2007)
54. Di, Y., "Homeostatic interactions between MEKK3 and TAK1 involved in NF-kappaB signaling", Cell Signal, 20, pp.705~713 (2008)
55. Xu, H., "MEK nuclear localization promotes YAP stability via sequestering beta-TrCP in KRAS mutant cancer cells", Cell Death Differ, 26, pp.2400~2415 (2019)
56. You, B., "Inhibition of ERK1", 2 down-regulates the Hippo, Oncotarget, pp.2015, 6[DOI]
57. Liang, N., "YAP enters the mTOR pathway to promote tuberous sclerosis complex", Mol. Cell Oncol, 2, pp.e998100~ (2015)
58. Lin, L., "The Hippo effector YAP promotes resistance to RAF-and MEK targeted cancer therapies", Nat. Genet, 47, pp.250~256 (2015)
59. Cerami, E., "The cBio cancer genomics portal : an open platform for exploring multidimensional cancer genomics data", Cancer Discov, 2, pp.401~404 (2012)
60. Wander, S. A., "The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4", 6 inhibitors in patients with hormone receptor positive metastatic breast cancer, 2020, pp.10, 1174~1193

관련 논문AI추천